Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study.

Mem Inst Oswaldo Cruz 2019 Mar 7;114:e180517. Epub 2019 Mar 7.

Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos, Bio-Manguinhos, Rio de Janeiro, RJ, Brasil.

Background: Field testing required to license the combined measles, mumps, and rubella (MMR) vaccine must take into account the current recommendation of the vaccine in Brazil: first dose at 12 months and second dose at 15 months of age in combination with a varicella vaccine.

Objectives: This study aimed to evaluate the clinical consistency, immunogenicity, and reactogenicity of three batches of MMR vaccine prepared with active pharmaceutical ingredients (API) from Bio-Manguinhos, Fiocruz (MMR-Bio), and compare it to a vaccine (MMR produced by GlaxoSmithKline) with different API.

Methods: This was a phase III, randomised, double-blind, non-inferiority study of the MMR-Bio administered in infants immunised at health care units in Pará, Brazil, from February 2015 to January 2016. Antibody levels were titrated by immunoenzymatic assays. Adverse events were recorded in diaries.

Findings: Seropositivity levels after MMR-Bio were 97.6% for measles, 84.7% for mumps, and 98.0% for rubella. After the MMRV vaccine, seroconversion rates and GMT increased substantially for mumps. In contrast, approximately 35% of the children had no detectable antibodies to varicella. Systemic adverse events were more frequent than local events.

Conclusion: The demonstration of batch consistency and non-inferiority of the Bio-MMR vaccine completed the technology transfer. This is a significant technological achievement with implications for immunisation programs.

Download full-text PDF

Source
http://dx.doi.org/10.1590/0074-02760180517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404515PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
March 2019
10 Reads

Publication Analysis

Top Keywords

measles mumps
8
mumps rubella
8
dose months
8
adverse events
8
mmr vaccine
8
vaccine
7
glaxosmithkline apimethods
4
mmr produced
4
apimethods phase
4
varicella systemic
4
produced glaxosmithkline
4
antibodies varicella
4
systemic adverse
4
iii randomised
4
study mmr-bio
4
mmr-bio administered
4
detectable antibodies
4
non-inferiority study
4
double-blind non-inferiority
4
vaccine mmr
4

References

(Supplied by CrossRef)

Imunizações Ministério da Saúde/Secretaria de Vigilância em Saúde/Departamento de Vigilância Epidemiológica/Coordenação-Geral do Programa Nacional de et al.
2013
Mumps vaccine. In SA Plotkin, WA Orestein, PA Offit, editors.
Rubin SA et al.
Vaccines 2013
Measles vaccine. In SA Plotkin, WA Orestein, PA Offit, editors.
Rubin SA et al.
Vaccines 2013
Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age
Stuck B et al.
Asian Pac J Allergy Immunol 2002

Similar Publications